Showing 501 - 520 results of 26,868 for search '(( 50 ((((ms decrease) OR (nn decrease))) OR (a decrease)) ) OR ( 50 we decrease ))', query time: 0.80s Refine Results
  1. 501
  2. 502
  3. 503

    Molecular Mimics of Classic P-Glycoprotein Inhibitors as Multidrug Resistance Suppressors and Their Synergistic Effect on Paclitaxel by Moustafa E. El-Araby (3626396)

    Published 2017
    “…On the other hand, combination of PTX and the non-cytotoxic Cur1-12V (10 μM) significantly decreased the IC<sub>50</sub> of PTX to 3.8 nM as well as the resistant fraction to 16.2%. …”
  4. 504
  5. 505

    Relationship between OLT and soil temperature at 50-cm (a), the depth at which charcoal was measured (b), and the active layer depth (c) measured in the field for a subset of the d... by Kristofer D Johnson (557206)

    Published 2013
    “…</strong> Relationship between OLT and soil temperature at 50-cm (a), the depth at which charcoal was measured (b), and the active layer depth (c) measured in the field for a subset of the data (<em>n</em> = 2179). …”
  6. 506
  7. 507
  8. 508
  9. 509
  10. 510
  11. 511
  12. 512
  13. 513
  14. 514

    Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  15. 515

    Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  16. 516

    Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  17. 517

    Evaluation of ethanol extract of Punica granatum (Pomegranate) peel decrease in viral replication of BoHV-1 in Colorado murine embryos experimentally infected by Eduardo Gimenes Palazzi (5671100)

    Published 2018
    “…The murine embryos treated with PgEE showed satisfactory results: no morphological changes, cleavage rate similar to controls, despite the detection of the presence of virus by nested PCR and TEM, there was a decrease of the viral titer after the treatment with this extract, which suggests interference of this treatment in the viral cycle BoHV-1 Colorado without altering the embryo development.…”
  18. 518

    Extracellular vesicles isolated from patients undergoing remote ischemic preconditioning decrease hypoxia-evoked apoptosis of cardiomyoblasts after isoflurane but not propofol expo... by Frederik Abel (8452101)

    Published 2020
    “…Prior isoflurane exposure <i>in vitro</i> even increased protection (RIPC-EVs/control, apoptotic ratio: 0.79; p = 0.0035; Sham-EVs/control, apoptotic ratio:1.04) while propofol (50μM) abrogated protection by RIPC-EVs (RIPC-EVs/control, Apoptotic ratio: 1.01; Sham-EVs/control, apoptotic ratio: 0.94; p = 0.602). …”
  19. 519
  20. 520